Will the price of oil collapse this year? Investors are worried they will and that could push refiners like�Phillips 66 (PSX) and PBF Energy (PBF) higher.
Bloomberg NewsHoward Weil’s Blake Fernandez and Richard Roberts explain:
We are witnessing a rotation from U.S. centric Independent E&P�� toward Independent Refiners in an effort to hedge the risk of collapsing domestic crude prices. From a global perspective, macro [refining & marketing] dynamics are improving into ��4 with significant crude supply growth placing a theoretical ceiling on oil prices / feedstock costs while underlying demand growth remains intact thereby supporting product prices…
That said we are recommending a slight tactical shift toward more defensive posturing with a focus on lower beta names and companies that screen at a discount from a valuation perspective. As a result, we are
downgrading [Delek US Holdings (DK)] and [Tesoro (TSO)] to Sector Perform and upgrading [Phillips 66] and [PBF Energy] to Sector Outperform.
Best Net Payout Yield Companies To Buy Right Now: Stemline Therapeutics Inc (STML)
Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.
SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.
SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk
SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.
SL-701
SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.
StemScreen-1
StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.
StemScreen-2
StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.
The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.
Advisors' Opinion:- [By Keith Speights]
Best-performing biotech IPO
Stemline Therapeutics� (NASDAQ: STML ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%. - [By David Zeiler]
3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.
- [By Jay Silverman]
Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.
Hot Defensive Stocks To Watch For 2014: Atlatsa Resources Corp (ATL)
Atlatsa Resources Corporation is engaged in mining, exploration and development of mineral deposits located in the Bushveld Igneous Complex (BIC), South Africa. The principal business activity is the mining and exploration of platinum group metals (PGM), through its mineral property interests. The Company�� subsidiaries include N1C Resources Incorporation, Anooraq Minera Mexicana, N2C Resources Incorporation, Plateau Resources Proprietary Limited, Bokoni Holdings Proprietary Limited, Bokoni Mines Proprietary Limited, Boikgantsho Proprietary Limited, Kwanda Proprietary Limited, Ga-Phasha Proprietary Limited, Middlepunt Hill Management Services (Proprietary) Limited and Lebowa Platinum Mine Limited. Advisors' Opinion:- [By Roberto Pedone]
Another stock that's starting to move within range of triggering a big breakout trade is Atlatsa Resources (ATL), which engages in the mining, exploration and development of platinum group metals properties located in the Bushveld Igneous Complex in South Africa. This stock has been on fire so far in 2013, with shares up a whopping 198%.
If you take a look at the chart for Atlatsa Resources, you'll notice that this stock has been uptrending strong for the last two months and change, with shares soaring higher from its low of 28 cents per share to its intraday high of 46 cents per share. During that uptrend, shares of ATL have been consistently making higher lows and higher highs, which is bullish technical price action. Shares of ATL have now started to take out some near-term overhead resistance levels at 43 cents to 44 cents per share. That move is quickly pushing shares of ATL within range of triggering another big breakout trade.
Market players should now look for long-biased trades in ATL if it manages to break out above its 52-week high at 50 cents per share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 170,178 shares. If that breakout hits soon, then ATL will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are its next major overhead resistance levels at 63 cents to 73 cents per share, or even 80 cents per share.
Traders can look to buy ATL off any weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of 39 cents per share, or near more support at 37 cents per share. One can also buy ATL off strength once it clears its 52-week high at 50 cents with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Hot Defensive Stocks To Watch For 2014: Huntington Bancshares Incorporated(HBAN)
Huntington Bancshares Incorporated operates as the holding company for The Huntington National Bank that provides commercial, small business, and consumer banking services. The company?s Retail and Business Banking segment offers various financial products and services, including checking, savings, and money market accounts, certificates of deposit, consumer loans, and small business loans and leases; and investments, insurance, interest rate risk protection, foreign exchange hedging, and treasury management services to consumer and small business customers. Its Regional and Commercial Banking segment provides commercial lending; depository and liquidity management products; treasury management solutions; equipment and technology leasing; international services; and capital markets services, such as interest rate risk protection, foreign exchange hedging and sales, trading of securities, mezzanine investment capabilities, and employee benefit programs to government, not-f or-profit, health-care, and publicly traded entities. The company?s Automobile Finance and Commercial Real Estate segment offers financing for the purchase of automobiles, and new and used vehicle inventory by automotive dealerships; and financing for land, buildings, and other commercial real estate owned or constructed by real estate developers, automobile dealerships, or other customers. Its Wealth Advisors, Government Finance, and Home Lending segment provides investment management; investment servicing; custody, and corporate trust and retirement plan services; and administrative and operational support to fund to high net worth customers. It also offers online, mobile, and telephone banking services; and operates approximately 1,300 automated teller machines. As of December 31, 2011, the company had 652 branches located in Ohio, Michigan, Pennsylvania, Indiana, West Virginia, and Kentucky. Huntington Bancshares Incorporated was founded in 1866 and is headquartered in Columbus, Ohio.
Advisors' Opinion:- [By Jay Jenkins]
For the big banks, the gap was greatest and overall scores were generally lower. It seems that battered institutions like Citigroup (NYSE: C ) and Bank of America� (NYSE: BAC ) are still trapped in the mud of 2007 and 2008. Regional banks contrast that, though, with banks like Huntington Bancshares� (NASDAQ: HBAN ) and Suntrust (NYSE: STI ) scoring higher and with less of a gap between customers and non customers.
- [By David Hanson and Matt Koppenheffer]
In this segment of The Motley Fool's everything-financials show,�Where the Money Is, banking analysts Matt Koppenheffer and David Hanson tell investors what they will be watching when PNC Financial Services (NYSE: PNC ) , Huntington Bancshares (NASDAQ: HBAN ) , and KeyCorp� (NYSE: KEY ) �report earnings this week
Hot Defensive Stocks To Watch For 2014: Grupo Simec S.A. de C.V. (SIM)
Grupo Simec, S.A.B. de C.V., together with its subsidiaries, engages in the manufacture, processing, and distribution of special bar quality (SBQ) steel and structural products primarily in the United States, Mexico, and Canada. Its steel products include I-beams; channels; structural and commercial angles; hot rolled bars, such as round, square, and hexagonal rods; flat bars; rebars; cold finished bars; wire rods; semi-finished tube rounds; and other semi-finished trade products. The company�s SBQ products are used in various engineered end-user applications, including axles, hubs, and crankshafts for automobiles and light trucks, machine tools, and off-highway equipment; and structural steel products are used in the non-residential construction market and other construction applications, as well as automotive industries. It also operates in Latin America, Europe, and Asia. The company was founded in 1969 and is headquartered in Guadalajara, Mexico. Grupo Simec, S.A.B. d e C.V. is a subsidiary of Industrias CH, S.A.B. de C.V.
Advisors' Opinion:- [By Daniel Cross]
Grupo Simec (NYSE: SIM) is a relatively obscure company with a $1.7 billion market cap that makes special bar-quality steel for North American markets. The company has significant downside protection in the form of its cash and cash equivalents of $623 million and total liabilities of just $665 million. Simec is also aggressively buying back stock. On a technical level, the relative strength index is hovering around 31, signaling that the stock may be oversold.
No comments:
Post a Comment